These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
494 related articles for article (PubMed ID: 20547904)
21. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related]
22. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. Boivin G; Goyette N; Farhan M; Ives J; Elston R J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003 [TBL] [Abstract][Full Text] [Related]
23. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Monforte V; Lopez C; Santos F; Zurbano F; de la Torre M; Sole A; Gavalda J; Ussetti P; Lama R; Cifrian J; Borro JM; Pastor A; Len O; Bravo C; Roman A Am J Transplant; 2009 May; 9(5):1134-41. PubMed ID: 19344437 [TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience. Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426 [TBL] [Abstract][Full Text] [Related]
26. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830 [TBL] [Abstract][Full Text] [Related]
28. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Park JM; Lake KD; Arenas JD; Fontana RJ Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460 [TBL] [Abstract][Full Text] [Related]
31. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A; Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208 [TBL] [Abstract][Full Text] [Related]
32. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644 [TBL] [Abstract][Full Text] [Related]
33. Two strategies for prevention of cytomegalovirus infections after liver transplantation. Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223 [TBL] [Abstract][Full Text] [Related]
34. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981 [TBL] [Abstract][Full Text] [Related]
35. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients. Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373 [TBL] [Abstract][Full Text] [Related]
36. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988 [TBL] [Abstract][Full Text] [Related]
37. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial. Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336 [TBL] [Abstract][Full Text] [Related]